TheraDoc Powers bioMerieux’s New Clinical Intervention Software System, STELLARA
TheraDoc(R), Inc., a Utah-based medical informatics company specializing in clinical decision-support technologies, has signed an industry exclusive agreement with bioMerieux, Inc., an international leader in the field of in vitro infectious disease diagnostics based in Marcy-l’Etoile, France.
Through this agreement, customized TheraDoc decision-support technology will power bioMerieux’s new clinical intervention software, STELLARA(TM).
“Be the First to Know” is more than just a slogan at bioMerieux; it’s the guiding philosophy behind the company’s continued dedication to the fight against disease and the search for appropriate treatments. STELLARA is designed to deliver actionable patient information to clinicians at the point-of-care, augmenting the microbiology results from bioMereiux’s leading BacT/ALERT(R) and VITEK(R) systems and providing real-time antibiotic monitoring and management.
STELLARA, embedded with TheraDoc’s technology, will provide clinicians with in-depth information about an organism and its level of resistance, resulting in more appropriately prescribed antibiotics, better decision-making, improved patient safety and quality of care, while reducing medical costs.
“STELLARA provides a solution to the field of biological diagnostics, an industry that has not previously benefited to a large degree from the comprehensive benefits of today’s information technologies,” noted TheraDoc’s president and CEO, Stanley Pestotnik. “We are optimistic about our partnership with bioMerieux and believe that ultimately, clinicians and their patients will be the greatest beneficiaries of our agreement.”
bioMerieux provides automated biological diagnostic systems to hospitals throughout the world, including more than 2,000 hospitals in the United States. The groundbreaking partnership provides the device manufacturer’s customers an integrated solution with advanced clinical intelligence — a trend with great potential. bioMerieux creates significant differentiation for its devices with the offering of STELLARA’s enhanced software technology and TheraDoc creates a new market stratum as both pursue their goal of safer, higher quality patient care.
STELLARA augments clinical decision-making by providing health care professionals with knowledge-enriched, disease-specific recommendations for antimicrobial management based on individual patient profiles and parameters, in addition to presenting microbiology results. The software is configurable, scalable to the institution’s needs, and mobile (PDA).
Powered by TheraDoc, STELLARA integrates individual electronic patient records with coded clinical data and focused medical informatics to provide clinicians with tools that enhance their ability to deliver high-quality evidence-based care. STELLARA uses proprietary inference engines developed by TheraDoc and multiple data sources from an institution’s existing information systems. The software provides easy electronic access to the recommendation logic and web-locatable reference articles(s) or proof sources. STELLARA is designed to effectively present important clinical results, allowing the clinician to make more timely and appropriate therapeutic treatment decisions.
The combination of bioMerieux’s extensive expertise in infectious disease diagnosis, along with their North American sales network and TheraDoc’s extensive experience in clinical medical-informatics systems promises to provide STELLARA users with the best of this exciting new technology.
About bioMerieux
As an international leader in the field of in vitro infectious disease diagnostics, bioMerieux designs, develops, manufactures and markets reagents and automated instruments for medical analyses and for cosmetics, and product quality control in the agri-food, cosmetics and pharmaceutical industries.
bioMerieux, based at Marcy-l’Etoile, France, employs 5,450 people throughout the world and counts 14 production sites distributed in France, the Netherlands, the United Kingdom, Italy, the United States, Brazil, Japan and Australia, as well as a European logistics center in France.
On the Net: www.biomerieux-usa.com
About TheraDoc, Inc.
TheraDoc is a medical informatics company specializing in therapeutic, real-time decision support that improves the quality, safety, and efficiency of patient care in large and small healthcare organizations. Integrated with disparate hospital information systems or electronic medical records, TheraDoc’s technology helps clinicians manage multiple processes of care across multiple conditions and diseases.
Founded in 1999, TheraDoc designs, develops, and supports a suite of clinical decision support technologies. TheraDoc’s founders and core medical informatics team are internationally recognized for their pioneering work in medical expert systems. Their experience in clinical decision support design and development spans two decades.
On the Net: TheraDoc’s site: www.theradoc.com
